<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547337</url>
  </required_header>
  <id_info>
    <org_study_id>ISLET-PET</org_study_id>
    <nct_id>NCT02547337</nct_id>
  </id_info>
  <brief_title>Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes</brief_title>
  <acronym>ISLET-PET</acronym>
  <official_title>Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes Using Positron Emission Tomography and Diffusion Weighted Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes is the major type of diabetes in the young. The pathophysiology still needs&#xD;
      clarification in order to reach feasible means of preventing the disease. This study aims in&#xD;
      defining the differences in pancreatic and intestinal blood flow between subjects with and&#xD;
      without type 1 diabetes and validating the methodology to achieve this. Earlier animal&#xD;
      studies have demonstrated changes in pancreatic islet blood flow using microspheres. The aim&#xD;
      of this study is to test and validate a method for the assessment of islet perfusion in&#xD;
      humans using molecular imaging. The investigators hypothesize that glucose-stimulated&#xD;
      pancreatic perfusion is enhanced specifically in islets in healthy subjects and that this&#xD;
      increase is mostly suppressed in subjects with type 1 diabetes.&#xD;
&#xD;
      Positron emission tomography (PET) is a non-invasive imaging technique, which can be used to&#xD;
      study flow and metabolism of different organs. Using radiowater ([15O]H2O) and PET, cellular&#xD;
      perfusion can be measured directly and noninvasively. Recently, diffusion weighted magnetic&#xD;
      resonance imaging (DWI) has also been applied as a complimentary method for the assessment to&#xD;
      quantitate changes in pancreatic blood flow.&#xD;
&#xD;
      In the study 10 healthy subjects and 10 subjects with type 1 diabetes will be imaged on two&#xD;
      separate days. Pancreatic and intestinal perfusion are first measured with [15O]H2O and&#xD;
      combined PET/magnetic resonance imaging before and 5 and 15 minutes after intravenous glucose&#xD;
      infusion. On the second day, PET imaging is replaced by dynamic DWI conducted in the same&#xD;
      time schedule and with intravenous glucose stimulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic islet blood flow acquired with PET and DWI (ml ml-1 min-1)</measure>
    <time_frame>within one study day</time_frame>
    <description>healthy subjects and subjects with T1DM are studied once using imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal blood flow acquired with PET and DWI (ml ml-1 min-1)</measure>
    <time_frame>within one study day</time_frame>
    <description>healthy subjects and subjects with T1DM are studied once using imaging</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, faeces&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects recruited via newspaper advertisements. Subjects with Type 1 diabetes&#xD;
        recruited at the policlinics of endocrinology and internal medicine in the district of&#xD;
        Turku University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria for healthy subjects&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Healthy as judged by history and examination&#xD;
&#xD;
          -  Age 18-30 years&#xD;
&#xD;
          -  Body mass index (BMI) 18 - 27 kg/m2&#xD;
&#xD;
          -  Normal 2 h oral glucose tolerance test&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Any chronic disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Blood pressure &gt; 140/90 mmHg&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Presence of any ferromagnetic objects in the body&#xD;
&#xD;
          -  Any other condition that could possibly create a hazard to the subject safety,&#xD;
             endanger the study procedures or interfere with the interpretation of the study&#xD;
             results&#xD;
&#xD;
        Criteria for subjects with type 1 diabetes (T1D)&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  T1D diagnosed at least 5 years ago&#xD;
&#xD;
          -  Age 18-30 years&#xD;
&#xD;
          -  BMI 18 - 30 kg/m2&#xD;
&#xD;
          -  Good or moderate glycemic control with long-acting insulin analogue combined with&#xD;
             injections of rapid-acting insulin&#xD;
&#xD;
          -  Uncomplicated T1D or with minor microvascular complications&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Any other condition or disease possibly affecting circulation, as evaluated by a&#xD;
             physician&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Blood pressure &gt; 140/90 mmHg&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Presence of any ferromagnetic objects in the body&#xD;
&#xD;
          -  Any other condition that could possibly create a hazard to the subject safety,&#xD;
             endanger the study procedures or interfere with the interpretation of the study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirjo Nuutila, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pirjo Nuutila, Prof.</last_name>
    <phone>+35823130000</phone>
    <email>pirnuu@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaakko MÃ¤kinen, MD</last_name>
    <phone>+35823130000</phone>
    <email>jaamak@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Pirjo Nuutila</investigator_full_name>
    <investigator_title>MD, Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

